INmune Bio Inc. Enters into Sales Agreement for Up to $65 Million in Common Stock

INmune Bio Inc. has entered into a Sales Agreement with A.G.P./Alliance Global Partners, appointing A.G.P. as the sales agent. Under this agreement, INmune Bio Inc. may offer and sell shares of its common stock, with a par value of $0.001 per share, up to an aggregate amount of $65,000,000. The company is not obligated to sell any shares and A.G.P. will use commercially reasonable efforts to sell the shares as directed by the company, including through "at the market" offerings as defined by the Securities Act. The agreement specifies that A.G.P. will receive a commission of 3.0% of the aggregate gross proceeds from each sale. The shares will be offered under the company's effective shelf registration statement on Form S-3, filed on May 1, 2024, and declared effective on August 7, 2024. The agreement includes customary closing conditions and provides A.G.P. with indemnification and contribution rights, as well as reimbursement for certain expenses. This filing details the terms of the Sales Agreement and related exhibits.